CO2024003723A2 - Compuestos de imidazopiridazina inhibidores de il-17 - Google Patents

Compuestos de imidazopiridazina inhibidores de il-17

Info

Publication number
CO2024003723A2
CO2024003723A2 CONC2024/0003723A CO2024003723A CO2024003723A2 CO 2024003723 A2 CO2024003723 A2 CO 2024003723A2 CO 2024003723 A CO2024003723 A CO 2024003723A CO 2024003723 A2 CO2024003723 A2 CO 2024003723A2
Authority
CO
Colombia
Prior art keywords
inhibitors
compounds
imidazopyridazine compounds
imidazopyridazine
syndrome
Prior art date
Application number
CONC2024/0003723A
Other languages
English (en)
Spanish (es)
Inventor
Dongpei Wu
Xiaohua Xue
Stefan Mccarver
Deane Gordon
Steven A Loskot
Steven P Meduna
Timothy B Rhorer
Kristen Song
Alexander E Valdes
Luke E Hanna
Douglas C Behenna
Steven D Goldberg
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of CO2024003723A2 publication Critical patent/CO2024003723A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CONC2024/0003723A 2021-09-27 2024-03-22 Compuestos de imidazopiridazina inhibidores de il-17 CO2024003723A2 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202163248566P 2021-09-27 2021-09-27
US202163273422P 2021-10-29 2021-10-29
US202263367546P 2022-07-01 2022-07-01
PCT/US2022/077001 WO2023049887A1 (en) 2021-09-27 2022-09-26 Imidazopyridazine il-17 inhibitor compounds

Publications (1)

Publication Number Publication Date
CO2024003723A2 true CO2024003723A2 (es) 2024-04-18

Family

ID=83692741

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2024/0003723A CO2024003723A2 (es) 2021-09-27 2024-03-22 Compuestos de imidazopiridazina inhibidores de il-17

Country Status (16)

Country Link
US (2) US12173007B2 (cg-RX-API-DMAC7.html)
EP (1) EP4408847A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024536869A (cg-RX-API-DMAC7.html)
KR (1) KR20240082369A (cg-RX-API-DMAC7.html)
AU (1) AU2022349687A1 (cg-RX-API-DMAC7.html)
CA (1) CA3233408A1 (cg-RX-API-DMAC7.html)
CL (1) CL2024000867A1 (cg-RX-API-DMAC7.html)
CO (1) CO2024003723A2 (cg-RX-API-DMAC7.html)
DO (1) DOP2024000051A (cg-RX-API-DMAC7.html)
IL (1) IL311751A (cg-RX-API-DMAC7.html)
JO (1) JOP20240059A1 (cg-RX-API-DMAC7.html)
MX (1) MX2024003772A (cg-RX-API-DMAC7.html)
PE (1) PE20240935A1 (cg-RX-API-DMAC7.html)
TW (1) TW202330530A (cg-RX-API-DMAC7.html)
UY (1) UY39958A (cg-RX-API-DMAC7.html)
WO (1) WO2023049887A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2022349687A1 (en) 2021-09-27 2024-05-16 Janssen Pharmaceutica Nv Imidazopyridazine il-17 inhibitor compounds
US12024507B2 (en) 2021-10-25 2024-07-02 Terns Pharmaceuticals, Inc. Compounds as GLP-1R agonists
TW202430165A (zh) 2022-12-02 2024-08-01 丹麥商理奧藥品公司 Il-17之小分子調節劑
AU2024213283A1 (en) * 2023-01-30 2025-08-14 Dice Alpha, Inc. Benzimidazole and aza-benzimidazole based il-17a modulators and uses thereof
EP4688156A1 (en) * 2023-03-28 2026-02-11 Janssen Pharmaceutica NV Lactam-containing imidazopyridazine il-17 inhibitor compounds
PE20252787A1 (es) 2023-04-07 2025-12-22 Terns Pharmaceuticals Inc Combinacion que comprende un agonista de thr-beta y un agonista de glp-1r para su uso en el tratamiento de un trastorno hepatico o una enfermedad cardiometabolica
WO2024215597A1 (en) * 2023-04-11 2024-10-17 Dice Alpha, Inc. Substituted 6-imidazopyridazine il-17a modulators and uses thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111601799B (zh) * 2018-01-15 2023-06-09 Ucb生物制药有限责任公司 作为Il-17调节剂的稠合咪唑衍生物
TWI752400B (zh) * 2019-01-07 2022-01-11 美商美國禮來大藥廠 Il-17a抑制劑
GB201909190D0 (en) 2019-06-26 2019-08-07 Ucb Biopharma Sprl Therapeutic agents
CN112341450B (zh) * 2019-08-09 2022-05-17 成都先导药物开发股份有限公司 一种免疫调节剂
WO2021098844A1 (zh) * 2019-11-20 2021-05-27 成都先导药物开发股份有限公司 一种免疫调节剂
WO2021170627A1 (en) * 2020-02-25 2021-09-02 UCB Biopharma SRL Difluorocyclohexyl derivatives as il-17 modulators
JP7664947B2 (ja) 2020-04-30 2025-04-18 ヤンセン ファーマシューティカ エヌ.ベー. Il-17の調節因子としてのイミダゾリダジン
WO2023025783A1 (en) 2021-08-23 2023-03-02 Leo Pharma A/S Small molecule modulators of il-17
AU2022349687A1 (en) 2021-09-27 2024-05-16 Janssen Pharmaceutica Nv Imidazopyridazine il-17 inhibitor compounds
CN116143777A (zh) 2021-11-04 2023-05-23 四川海思科制药有限公司 一种可抑制il-17a的杂环化合物及其用途

Also Published As

Publication number Publication date
TW202330530A (zh) 2023-08-01
JOP20240059A1 (ar) 2024-03-26
WO2023049887A1 (en) 2023-03-30
PE20240935A1 (es) 2024-04-30
JP2024536869A (ja) 2024-10-08
KR20240082369A (ko) 2024-06-10
UY39958A (es) 2023-04-28
US20230143050A1 (en) 2023-05-11
AU2022349687A1 (en) 2024-05-16
MX2024003772A (es) 2024-06-19
DOP2024000051A (es) 2024-11-15
CL2024000867A1 (es) 2024-09-23
CA3233408A1 (en) 2023-03-30
EP4408847A1 (en) 2024-08-07
US20250109137A1 (en) 2025-04-03
IL311751A (en) 2024-05-01
US12173007B2 (en) 2024-12-24

Similar Documents

Publication Publication Date Title
CO2022017072A2 (es) Imidazopiridazinas como moduladores de il-17
DOP2024000051A (es) Compuestos de imidazopiridazina inhibidores de il-17
UY39957A (es) Compuestos de imidazopiridazina inhibidores de il-17
MX2022013650A (es) Imidazopirimidinas como moduladores de il-17.
DOP2019000168A (es) Compuestos de amino-triazolopiridina y su uso en el tratamiento del cáncer
CO2020015758A2 (es) Compuestos de purinona y su uso en el tratamiento del cáncer
MX2024009943A (es) Inhibidores de arn helicasa dhx9 y usos de los mismos
MX2020003415A (es) Compuestos de benzoxacepina oxazolidinona y métodos de uso.
CR11510A (es) Uso de un inhibidor de la gamma-secretasa para tratamiento del cancer
DE602007014186D1 (de) Triazin-11-beta-hydroxysteroid-dehydrogenase-artige hemmer
ECSP088306A (es) Agentes para prevenir y tratar los trastornos que involucran la modulación de los receptores ryr
CL2019002900A1 (es) Análogos de benzoazepina como agentes inhibidores de la tirosina cinasa de bruton.
UY30628A1 (es) Inhibidores de metaloproteasas de matriz
MX389545B (es) Compuestos terapeuticos y composiciones para el tratamiento de trastornos sociales y trastornos de uso de sustancias.
ECSP14013263A (es) Inhibidores de la enzima activadora de nedd8
MX2022006176A (es) Terapia combinada que comprende un inhibidor de alk2 y un inhibidor de jak2.
MX2022012575A (es) Compuestos para usarse para tratar la enfermedad de huntington.
ECSP19019613A (es) Compuestos de aza–indazol para usar en lesiones de tendones y/o ligamentos
CL2023000857A1 (es) Inhibidores line-1 para tratar la enfermedad
AR087902A1 (es) COMPOSICIONES Y METODOS PARA TRATAR EL CANCER USANDO EL INHIBIDOR DE PI3Kb Y EL INHIBIDOR DE LA VIA DE MAPK, INCLUIDOS LOS INHIBIDORES DE MEK Y RAF
CL2011001829A1 (es) 3'-n-desmetil-4''-o-(2-dietilaminoetanoil)-6-o-metil-9a-aza-9a-homoeritromicina a, sus sales y formas cristalinas 1, 2 y 3; proceso de preparacion; uso para tratar enfermedades inflamatorias; composicion farmaceutica; y composicion que ademas comprende otro compuesto activo.
ES2582660T3 (es) Sidnoniminas - inhibidores específicos de la recaptación de la dopamina y su uso en el tratamiento de los trastornos relacionados con la dopamina
MX2021009488A (es) Uso de vibegron para tratar la vejiga hiperactiva.
CL2025000078A1 (es) Formas sólidas de un derivado de triazina como modulador cbl-b
CL2022002989A1 (es) Imidazopiridazinas como moduladores de il-17.